{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:49:22Z","timestamp":1782107362008,"version":"3.54.5"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FOR5489-P8"],"award-info":[{"award-number":["FOR5489-P8"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70112525, 70114549"],"award-info":[{"award-number":["70112525, 70114549"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Genetic mutations disrupting interferon (IFN) signaling have been described as an evolutionary route for tumor cells to evade immune checkpoint inhibitor (ICI) therapy. We hypothesized that loss of IFN signaling not only enables cancer cells to evade immune surveillance, but also renders them susceptible to oncolytic viruses. To experimentally address this hypothesis, we generated IFN-unresponsive mouse melanoma cell variants via CRISPR\/Cas9 and investigated the impact of sequential immuno-virotherapy on their evolutionary dynamics in immunocompetent syngeneic hosts. In wild-type mice, Natural Killer (NK) cells eliminated IFN-unresponsive subclones in mixed tumor cell transplants due to their very low expression of major histocompatibility complex class I (MHC-I) molecules. Upon NK cell depletion, IFN-unresponsive subclones established and were preferentially selected by T cell-directed immunotherapy, consistent with observations in patients. Sequential oncolytic virotherapy was able to specifically target and counter-select these IFN-unresponsive clones. Unexpectedly, IFN-responsive tumor cells re-emerged with a dedifferentiated phenotype that resisted both immune and viral control. Together, these findings touch upon the paradoxical anti- and pro-tumoral roles of cancer cell-intrinsic IFN signaling and highlight dedifferentiation as a potential convergent resistance mechanism that ultimately limits the efficacy of both treatment approaches. Our findings may provide an explanation for why combination immunotherapy and oncolytic virotherapy did not meet clinical expectations.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1875225","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:39:08Z","timestamp":1782106748000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncolytic virotherapy counteracts the selection of IFN-unresponsive cancer cells post-immunotherapy but is limited by the emergence of dedifferentiated cancer cells"],"prefix":"10.3389","volume":"17","author":[{"given":"Susan","family":"Gellert","sequence":"first","affiliation":[{"name":"Laboratory of Experimental Dermatology, Department of Dermatology, University Hospital and Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke-University","place":["Magdeburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Kruse","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Dermatology, Department of Dermatology, University Hospital and Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke-University","place":["Magdeburg, Germany"]},{"name":"Department of Experimental Immunology, Institute of Immunology, Eberhard Karls University of T\u00fcbingen","place":["T\u00fcbingen, Germany"]},{"name":"M3 Research Center, University Hospital T\u00fcbingen, University of T\u00fcbingen","place":["T\u00fcbingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Peters","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Dermatology, Department of Dermatology, University Hospital and Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke-University","place":["Magdeburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Bonifatius","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Dermatology, Department of Dermatology, University Hospital and Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke-University","place":["Magdeburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"T\u00fcting","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Dermatology, Department of Dermatology, University Hospital and Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke-University","place":["Magdeburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Buzzai","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Dermatology, Department of Dermatology, University Hospital and Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke-University","place":["Magdeburg, Germany"]},{"name":"The Kids Research Institute Australia","place":["Nedlands, WA, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The next decade of immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov"},{"key":"B2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005755","article-title":"Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0458","article-title":"Immune cell\u2013poor melanomas benefit from PD-1 blockade after targeted type I IFN activation","volume":"4","author":"Bald","year":"2014","journal-title":"Cancer Discov"},{"key":"B7","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ccell.2020.08.005","article-title":"Conserved interferon-\u03b3 signaling drives clinical response to immune checkpoint blockade therapy in melanoma","volume":"38","author":"Grasso","year":"2020","journal-title":"Cancer Cell"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nature23270","article-title":"In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target","volume":"547","author":"Manguso","year":"2017","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2017.09.008","article-title":"Checkpoint blockade plus oncolytic virus: a hot therapeutic cancer strategy","volume":"23","author":"Robert","year":"2017","journal-title":"Trends Mol Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-018-0074-6","article-title":"JAK\/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models","volume":"26","author":"Patel","year":"2019","journal-title":"Cancer Gene Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3365","article-title":"Mutations in the IFN\u03b3-JAK-STAT pathway causing resistance to immune checkpoint inhibitors in melanoma increase sensitivity to oncolytic virus treatment","volume":"27","author":"Nguyen","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06199-x","article-title":"CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours","volume":"618","author":"Kruse","year":"2023","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1101\/gr.176701.114","article-title":"OutKnocker: a web tool for rapid and simple genotyping of designer nuclease edited cell lines","volume":"24","author":"Schmid-Burgk","year":"2014","journal-title":"Genome Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2214","article-title":"Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice","volume":"66","author":"V\u00e4h\u00e4-Koskela","year":"2006","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22758","article-title":"Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models","volume":"121","author":"M\u00e4\u00e4tt\u00e4","year":"2007","journal-title":"Int J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.53","article-title":"Interferon-\u03b2 sensitivity of tumor cells correlates with poor response to VA7 virotherapy in mouse glioma models","volume":"20","author":"Ruotsalainen","year":"2012","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0579","article-title":"Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy","volume":"69","author":"Kohlmeyer","year":"2009","journal-title":"Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nature11538","article-title":"Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation","volume":"490","author":"Landsberg","year":"2012","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1016\/j.celrep.2019.08.017","article-title":"Natural killer cells suppress T cell-associated tumor immune evasion","volume":"28","author":"Freeman","year":"2019","journal-title":"Cell Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/s41467-020-14290-4","article-title":"Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-\u03b3-signaling mutant cancer cells","volume":"11","author":"Williams","year":"2020","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.omto.2022.03.006","article-title":"IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor T cell activity","volume":"25","author":"El-Sayes","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200826","article-title":"Oncolytic vesicular stomatitis virus alone or in combination with JAK inhibitors is effective against ovarian cancer","volume":"32","author":"Geoffroy","year":"2024","journal-title":"Mol Ther Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.cell.2023.11.037","article-title":"A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma","volume":"187","author":"Pozniak","year":"2024","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","article-title":"A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade","volume":"175","author":"Jerby-Arnon","year":"2018","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1038\/s41467-020-17739-8","article-title":"Reversal of pre-existing NGFR-driven tumor and immune therapy resistance","volume":"11","author":"Boshuizen","year":"2020","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.cell.2017.11.018","article-title":"Intrinsic immunity shapes viral resistance of stem cells","volume":"172","author":"Wu","year":"2018","journal-title":"Cell"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nature12862","article-title":"Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity","volume":"505","author":"Schoggins","year":"2014","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0809242105","article-title":"An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer","volume":"105","author":"Weichselbaum","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","article-title":"Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade","volume":"178","author":"Benci","year":"2019","journal-title":"Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01315-x","article-title":"In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer","volume":"23","author":"Dubrot","year":"2022","journal-title":"Nat Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.013","article-title":"Mutations in IFN-\u03b3 signaling genes sensitize tumors to immune checkpoint blockade","volume":"41","author":"Song","year":"2023","journal-title":"Cancer Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1101\/2024.08.13.607862","article-title":"Targeting interferon-driven inflammatory memory prevents epigenetic evolution of cancer immunotherapy resistance","author":"Qiu","year":"2024"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade8520","article-title":"JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma","volume":"384","author":"Zak","year":"2024","journal-title":"Science"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1126\/science.adf1329","article-title":"Combined JAK inhibition and PD-1 immunotherapy for non\u2013small cell lung cancer patients","volume":"384","author":"Mathew","year":"2024","journal-title":"Science"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09188-4","article-title":"Humoral determinants of checkpoint immunotherapy","volume":"644","author":"Dai","year":"2025","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.05.004","article-title":"Oncolytic herpes virus G47\u0394 works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation","volume":"22","author":"Sugawara","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0405","article-title":"Recombinant orthopoxvirus primes colon cancer for checkpoint inhibitor and cross-primes T cells for antitumor and antiviral immunity","volume":"20","author":"Kim","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B42","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.omto.2019.09.001","article-title":"STING restricts oHSV replication and spread in resistant MPNSTs but is dispensable for basal IFN-stimulated gene upregulation","volume":"15","author":"Lee","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.30574\/wjarr.2024.21.1.2585","article-title":"Modulating the immunosuppressive tumor microenvironment: Multi-synergistic cancer therapeutic approach with oncolytic viruses","volume":"21","author":"Bayode","year":"2024","journal-title":"World J Adv Res Rev"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01206-1","article-title":"Oncolytic viruses as anticancer agents: clinical progress and remaining challenges","volume":"406","author":"Appleton","year":"2025","journal-title":"Lancet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1875225\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:39:09Z","timestamp":1782106749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1875225\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":44,"alternative-id":["10.3389\/fimmu.2026.1875225"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1875225","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"article-number":"1875225"}}